Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China.
Molecules. 2011 Aug 9;16(8):6758-68. doi: 10.3390/molecules16086758.
Parthenolide, the principal component of sesquiterpene lactones present in medical plants such as feverfew (Tanacetum parthenium), has been reported to have anti-tumor activity. In this study, we evaluated the therapeutic potential of parthenolide against bladder cancer and its mechanism of action. Treatment of bladder cancer cells with parthenolide resulted in a significant decrease in cell viability. Parthenolide induced apoptosis through the modulation of Bcl-2 family proteins and poly (ADP-ribose) polymerase degradation. Treatment with parthenolide led to G1 phase cell cycle arrest in 5637 cells by modulation of cyclin D1 and phosphorylated cyclin-dependent kinase 2. Parthenolide also inhibited the invasive ability of bladder cancer cells. These findings suggest that parthenolide could be a novel therapeutic agent for treatment of bladder cancer.
小白菊内酯是倍半萜内酯的主要成分，存在于一些药用植物中，如小白菊（Tanacetum parthenium），已被报道具有抗肿瘤活性。在这项研究中，我们评估了小白菊内酯对膀胱癌的治疗潜力及其作用机制。小白菊内酯处理膀胱癌细胞可显著降低细胞活力。小白菊内酯通过调节 Bcl-2 家族蛋白和聚（ADP-核糖）聚合酶降解诱导细胞凋亡。小白菊内酯通过调节细胞周期蛋白 D1 和磷酸化细胞周期蛋白依赖性激酶 2 使 5637 细胞停滞在 G1 期。小白菊内酯还抑制了膀胱癌细胞的侵袭能力。这些发现表明，小白菊内酯可能是治疗膀胱癌的一种新型治疗剂。
